Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) was upgraded by equities research analysts at Vetr from a “buy” rating to a “strong-buy” rating in a note issued to investors on Tuesday. The firm presently has a $19.72 price objective on the specialty pharmaceutical company’s stock. Vetr‘s price target indicates a potential upside of 12.75% from the stock’s current price.

Other research analysts have also issued reports about the stock. Jefferies Group restated a “buy” rating and set a $18.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Thursday, August 10th. Stifel Nicolaus restated a “buy” rating and set a $35.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Thursday, August 10th. Cantor Fitzgerald set a $23.00 price objective on shares of Valeant Pharmaceuticals International and gave the stock a “buy” rating in a research note on Wednesday, August 16th. ValuEngine upgraded shares of Valeant Pharmaceuticals International from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. Finally, TD Securities upgraded shares of Valeant Pharmaceuticals International from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research note on Friday, November 3rd. Five analysts have rated the stock with a sell rating, eleven have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $17.46.

Shares of Valeant Pharmaceuticals International (NYSE:VRX) opened at $17.49 on Tuesday. The company has a debt-to-equity ratio of 4.84, a quick ratio of 1.03 and a current ratio of 1.26. Valeant Pharmaceuticals International has a 52-week low of $8.31 and a 52-week high of $18.25. The company has a market cap of $6,090.00, a PE ratio of 2.80, a price-to-earnings-growth ratio of 0.47 and a beta of -0.22.

In related news, Director John Paulson purchased 344,216 shares of the firm’s stock in a transaction that occurred on Thursday, November 16th. The shares were acquired at an average price of $14.40 per share, for a total transaction of $4,956,710.40. Following the purchase, the director now owns 94,559 shares in the company, valued at $1,361,649.60. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 5.87% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Moors & Cabot Inc. grew its stake in Valeant Pharmaceuticals International by 55.0% in the 3rd quarter. Moors & Cabot Inc. now owns 23,675 shares of the specialty pharmaceutical company’s stock valued at $337,000 after buying an additional 8,400 shares during the last quarter. Janney Montgomery Scott LLC grew its stake in Valeant Pharmaceuticals International by 33.7% in the 3rd quarter. Janney Montgomery Scott LLC now owns 20,095 shares of the specialty pharmaceutical company’s stock valued at $288,000 after buying an additional 5,069 shares during the last quarter. Cubist Systematic Strategies LLC grew its stake in Valeant Pharmaceuticals International by 9,253.2% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 56,119 shares of the specialty pharmaceutical company’s stock valued at $804,000 after buying an additional 55,519 shares during the last quarter. AMP Capital Investors Ltd grew its stake in Valeant Pharmaceuticals International by 6.3% in the 3rd quarter. AMP Capital Investors Ltd now owns 142,910 shares of the specialty pharmaceutical company’s stock valued at $2,043,000 after buying an additional 8,484 shares during the last quarter. Finally, Stifel Financial Corp grew its stake in Valeant Pharmaceuticals International by 18.4% in the 3rd quarter. Stifel Financial Corp now owns 236,576 shares of the specialty pharmaceutical company’s stock valued at $3,384,000 after buying an additional 36,705 shares during the last quarter. Institutional investors and hedge funds own 49.49% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://theolympiareport.com/2017/12/05/valeant-pharmaceuticals-international-vrx-lifted-to-strong-buy-at-vetr.html.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.